Target intelligence / Profile preview

Up-frameshift protein 1 (UPF1)

Target
UPF1
Molecular classification
Enzyme, RNA helicase (Superfamily 1 helicase), ATPase, RNA-binding protein
01

Overview

Up-frameshift protein 1 (UPF1) is a highly conserved ATP-dependent RNA helicase and ATPase that plays a central role in the nonsense-mediated mRNA decay (NMD) pathway, a fundamental mRNA surveillance mechanism that degrades messenger RNAs containing premature stop codons and regulates the abundance of many normal mRNAs[2][4]. UPF1 operates as a monomeric helicase with high processivity on nucleic acids; it translocates along and unwinds RNA secondary structures using energy from ATP hydrolysis[1][2][3][4]. The protein has a structurally unique helicase core with two RecA-like domains and subdomains critical for RNA binding and regulation[1][2]. UPF1 function is dynamically regulated—its ATPase activity is autoinhibited until activated by interacting proteins such as UPF2, which is essential for efficient NMD[3]. Mutations in UPF1 can disrupt NMD and are implicated in several human diseases, particularly cancer and neurodegeneration[2][3][4]. While there are no approved drugs directly targeting UPF1, its pivotal role in RNA surveillance makes it an attractive candidate for future therapeutic modulation, albeit with significant safety considerations due to the essential nature of NMD in cell homeostasis.

Other names
Regulator of nonsense transcripts 1RENT1SMG2
02

Mechanism of action

Molecules (not yet specific drugs) targeting UPF1 could modulate NMD through inhibition or activation of its helicase or ATPase activity, affecting mRNA decay.

03

Biological functions

Nonsense-mediated mRNA decay (NMD)RNA surveillance and quality controlATP-dependent unwinding of RNA secondary structuresmRNA degradationRegulation of telomere maintenance and telomerase activity
04

Disease associations

CancerNeurodegenerative diseaseOther genetic diseases involving impaired RNA surveillance
05

Safety considerations

General concerns for targeting UPF1 include risk of widespread effects on mRNA stability and protein synthesis, leading to unintended cellular stress or toxicity, especially if NMD is broadly inhibited.
06

Biomarkers

UPF1 expression or phosphorylation status may be used to monitor activity in NMD-related research but has not been established as a standard clinical biomarker.

Beyond the preview

Go deeper on Up-frameshift protein 1 (UPF1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Up-frameshift protein 1 (UPF1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call